Therapeutic interventions for enhancing collateral development by administration of growth factors: Basic principles, early results and potential hazards

Cardiovascular Research

Volumn 49, Issue 3, 2001, Pages 532-542

  Epstein, Stephen E ^a   Fuchs, Shmuel ^a   Zhou, Yi Fu ^a   Baffour, Richard ^a   Kornowski, Ran ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Angiogenesis; Collateral circulation; Coronory circulation; Growth factors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; COLLATERAL CIRCULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; GENE THERAPY; HUMAN; ISCHEMIC HEART DISEASE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; SYMPTOM; TREATMENT PLANNING; TUMOR;

ANIMALS; CAPILLARY PERMEABILITY; COLLATERAL CIRCULATION; CORONARY CIRCULATION; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DOGS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GROWTH SUBSTANCES; HYPOTENSION; LYMPHOKINES; NEOVASCULARIZATION, PHYSIOLOGIC; RANDOMIZED CONTROLLED TRIALS; STRESS, MECHANICAL; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035895767     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00217-0     Document Type: Review

References (113)

1. The development of a new blood supply to the heart by operation
2. An experimental method of providing a collateral circulation to the heart
3. Cardio-omentopexy and implantation of multiple loops for revascularization of the heart
4. De-epicardialization. A simple, effective surgical treatment for angina pectoris
5. Experimental revascularization of the entire heart. Evaluation of epicardiectomy, omental graft, and/or implantation of the internal mammary artery in preventing myocardial necrosis and death of the animal
6. Heparin promotes the formation of extracardiac to coronary anastomoses in a canine model
7. A model to assess interventions to improve collateral blood flow: Continuous administration of agents into the left coronary artery in dogs
8. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study
9. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth medicated by tumor-secreted products
10. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
11. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
12. Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium
13. Human vascular permeability factor. Isolation from U937 cells
14. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF
15. Pituitary fibroblast growth factors. Partial purification and characterization
16. Identification and partial purification of fibroblast growth factor from the brains of developing rats and leucodystrophic mutant mice
17. Retina- and eye-derived endothelial cell growth factors: Partial molecular characterization and identity with acidic and basic fibroblast growth factors
18. Isolation and partial characterization of an endothelial cell growth factor from the bovine kidney homology with basic fibroblast growth factor
19. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
20. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
21. Molecular and biological properties of the vascular endothelial growth factor family of proteins
22. Purification and biological properties of vasculotropin, a new angiogenic cytokine
23. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
24. Vascular endothelial growth factor is a secreted angiogenic mitogen
25. 165 and PDGF-BB
26. Signaling vascular morphogenesis and maintenance
27. Angiopoietin-1 induces sprouting angiogenesis in vitro
28. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
29. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
30. Effect of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart
31. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs
32. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor
33. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
34. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs
35. Pharmacodynamics of basic fibroblast growth factor: Route of administration determines myocardial and systemic distribution
36. VEGF administration in chronic myocardial ischemia in pigs
37. Development of coronary collateral circulation in left circumflex Ameriod-occluded swine myocardium
38. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
39. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor
40. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
41. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
42. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
43. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery (abs)
44. Efficient gene transfer into myocardium by direct injection of adenovirus vectors
45. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for VEGF-12, improves myocardial perfusion and function in the ischemic porcine heart
46. Catheter-based myocardial gene transfer utilizing nonfluoroscopic electromechanical left ventricular mapping
47. Electromagnetic guidance for catheter-based transendocardial injection: A platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models
48. Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease
49. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results
50. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a Phase I randomized, double-blind, placebo-controlled trial
51. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
52. Intracoronary administration of recombinant fibroblast growth factor-2 in patients with severe coronary artery disease. Results of Phase I
53. Angiogenesis therapy with recombinant bFGF
54. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
55. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
56. Magnitude and location of new angiographically apparent coronary callaterals following intravenous VEGF administration
57. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial
58. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial
59. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in-patient with ischaemic limb
60. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
61. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results
62. Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial
63. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect
64. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
65. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
66. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
67. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
68. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning
69. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
70. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
71. 2 homeostasis
72. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia
73. Purification and characterization of hypoxia-inducible factor 1
74. Dimerization. DNA binding, and transactivation properties of hypoxia-inducible factor 1
75. 2 tension
76. PR39, a peptide regulator of angiogenesis
77. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
78. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion
79. The pathophysiology of the collateral circulation (arteriogenesis)
80. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia
81. Effects of acidic fibroblast growth factor on normal and ischemic myocardium
82. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
83. 2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat
84. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
85. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasias in guinea pigs. Role of cellular immunity, myofribroblasts, microvascular damage, and infarction in line 1 tumor regression
86. 2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor
87. Angiopoietin-1 protects the adult vasculature against plasma leakage
88. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state
89. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis
90. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells
91. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
92. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
93. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries: A possible role in the pathophysiology of atherosclerosis
94. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance
95. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia
96. Angiogenesis in human coronary atherosclerotic plaques
97. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults
98. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
99. VEGF gene delivery to myocardium: Deleterious effects of unregulated overexpression
100. VPF/VEGF induced angiogenesis
101. Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: Reversal by suramin
102. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo
103. VEGF gene delivery to myocardium: Deleterious effects of unregulated overexpression
104. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
105. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - Angiogenesis and angioma formation
106. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo
107. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries
108. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
109. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: An effective tool for the in vivo study of arterial diseases
110. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
111. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
112. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism
113. Hypotensive activity of fibroblast growth factor